|
Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma Clinical research trials and Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma. Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma clinical trial. Test subjects typically obtain the finest healthcare available for their Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma  Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
For Condition: Lymphoma, Non-Hodgkin
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) ,
Synopsis: When patients relapse after primary chemotherapy for Non-Hodgkin's lymphoma, they may be eligible to receive high-dose chemotherapy with autologous stem cell support. Unfortunately high-dose chemotherapy is curative in less than half the patients who receive it. This study is being conducted to determine the safety, side effects, and the ability to respond to an investigational vaccine that consists of tumor-pulsed dendritic cells given with an immune stimulating drug called interleukin-2. The patient must have a lymphomatous node accessible for excision to prepare the vaccine. Dendritic cells are immune cells that are obtained from the blood, and are important in the body's immune response to foreign substances. This study will examine the response of the immune system after three vaccinations (composed of dendritic cells, which have been exposed to dead fragments of lymphoma cells) given beginning three months after transplant. Vaccination may result in sensitizing the patient's dendritic cells to his lymphoma cells, potentially resulting in an immune response against the lymphoma. Twelve patients will be treated on study.
Details:
Eligibility:
Study Type: Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 10 Years/70 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Histologically documented, aggressive and/or intermediate grade NHL, B-cell and T-cell. - In relapse after first-line conventional chemotherapy. Primary therapy should include a doxorubicin-based regimen. - Patients must have disease sensitive to induction chemotherapy, radiation therapy, and/or radioimmunotherapy. Successful treatment of CNS or meningeal disease is allowed. - Patients must have accessible tumor for biopsy or excision. - Cumulative total doxorubicin: <500 mg/m2 - Performance score 0-2 - No prior pelvic RT - Patients with a prior malignancy are eligible if they were treated for cure and have no evidence of active disease. - Patients may not be taking immunosuppressive agents. - Informed Consent; IRB approval
Total Enrollment:
Location and Contact Information:
University of Michigan Medical Center
Ann Arbor, Michigan, 48104-0914
United States
Additional Information:
Study ID Numbers: NCRR-M01RR00042-1694; M01RR00042
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006434
Other Lymphoma, Non-Hodgkin Studies:
1. Randomized double cord blood transplant study
2. Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
3. Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
4. A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects with Refractory Lymphoma
5. The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients with AIDS-Related Lymph Node Cancer
Related Studies:
Other Lymphoma, Non-Hodgkin Clinical Trials
Other Michigan Clinical Trials
Other Ann Arbor Clinical Trials
Tumor Lysate Pulsed-Dendritic Cell Vaccines after High-Dose Chemotherapy for Non-Hodgkin's Lymphoma
|
|
|
|
|
|
|
|
